World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
